Compare ETON & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ETON | BOLD |
|---|---|---|
| Founded | 2017 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 689.8M | 36.5M |
| IPO Year | 2018 | 2024 |
| Metric | ETON | BOLD |
|---|---|---|
| Price | $23.54 | $1.55 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | ★ $39.33 | $4.00 |
| AVG Volume (30 Days) | ★ 424.7K | 397.0K |
| Earning Date | 05-12-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 32.47 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $79,950,000.00 | N/A |
| Revenue This Year | $40.90 | N/A |
| Revenue Next Year | $47.23 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 104.94 | N/A |
| 52 Week Low | $13.09 | $0.96 |
| 52 Week High | $27.29 | $1.78 |
| Indicator | ETON | BOLD |
|---|---|---|
| Relative Strength Index (RSI) | 49.27 | 67.19 |
| Support Level | $16.23 | $1.08 |
| Resistance Level | $27.29 | $1.55 |
| Average True Range (ATR) | 1.15 | 0.09 |
| MACD | -0.53 | 0.04 |
| Stochastic Oscillator | 5.18 | 77.87 |
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has eight commercial rare disease products, INCRELEX, ALKINDI SPRINKLE, KHINDIVITM, GALZIN, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous and Nitisinone. It also has five additional product candidates in late-stage development: ET-600, Amglidia, ET-700, ET-800 and ZENEO hydrocortisone autoinjector.
Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.